The scale of the problem is staggering. In 2010, an estimated 35.6 million people worldwide were living with dementia, a figure projected to reach 65.7 million by 2030 and 115.4 million by 2050. Alzheimer’s disease, the most common neurodegenerative condition, affects roughly one in ten adults over the age of 65, while Parkinson’s disease is the second most prevalent, with prevalence rising sharply in older populations. Current diagnostic practice depends on clinical evaluation, neuroimaging such as MRI and PET, and laboratory analysis of cerebrospinal fluid, but these approaches are costly, often inaccessible, and typically confirm a diagnosis only after symptoms have emerged. Because the underlying pathology, the accumulation of misfolded proteins like amyloid-beta, tau, alpha-synuclein, and pathological prion protein, can begin years or even decades before clinical onset, researchers have increasingly turned to biosensors as a way to detect these molecular signatures early, cheaply, and minimally invasively.

Biosensors work by coupling a biological recognition element, such as an antibody, aptamer, enzyme, or molecularly imprinted polymer, to a transducer that converts binding events into measurable electrical, optical, or mechanical signals. For neurodegenerative diseases, the analytical demands are extreme: disease biomarkers circulate at vanishingly small concentrations in blood, plasma, cerebrospinal fluid, saliva, and even interstitial fluid, and the sample volumes available for testing are often tiny. The review highlights how nanostructured sensing interfaces, including gold nanoparticles, carbon nanotubes, graphene, reduced graphene oxide, and quantum dots, have dramatically amplified signals and expanded the effective surface area of electrodes, pushing detection limits into the femtomolar and even attomolar ranges.

In the Alzheimer’s disease arena, the progress is particularly striking. Rushworth and colleagues built a label-free impedimetric biosensor that specifically recognizes soluble amyloid-beta oligomers, the neurotoxic species most closely tied to early synaptic dysfunction, achieving detection down to 0.5 picomolar. Field-effect transistor platforms have detected amyloid-beta in human serum at 1 picogram per milliliter in real time, while hydrogel-enhanced dielectrophoretic systems reached roughly 0.15 picograms per milliliter and, crucially, distinguished Alzheimer’s patients from cognitively healthy individuals in a cohort of 24 with 95.83 percent accuracy using the amyloid-beta 1-40/1-42 signal ratio. Microfluidic lab-on-a-chip devices with valve-controlled flow, photonic microring resonators, and surface-enhanced Raman spectroscopy integrated into microfluidic channels have all pushed amyloid detection to picomolar and sub-picomolar thresholds while shrinking sample and reagent requirements.

Tau protein biosensors tell a similar story of accelerating sophistication. Disposable reduced graphene oxide and gold nanoparticle platforms have measured Tau-441 in cerebrospinal fluid and serum with detection limits as low as 0.091 picograms per milliliter, while photoelectrochemical aptasensors using molybdenum diselenide nanosheets decorated with gold nanoparticles detected Tau-381 down to 0.3 femtomolar. An immunosensor built on multiwalled carbon nanotubes and platinum nanoparticles achieved a detection limit of 0.24 picograms per milliliter for phosphorylated Tau-181, a biomarker of early-stage disease, with strong recovery rates in serum. Perhaps most visionary is a fully integrated wearable patch that samples interstitial fluid through hollow microneedles, detects phosphorylated Tau-181 and Tau-217 with cutoff values below 0.1 picograms per milliliter, and streams results to a smartphone via Bluetooth, validated in mouse models of Alzheimer’s disease.

For Parkinson’s disease, the biomarker landscape centers on alpha-synuclein, DJ-1, dopamine, and neuronal extracellular vesicles. Impedimetric sensors on graphene oxide-modified gold microelectrode arrays have quantified alpha-synuclein autoantibodies in undiluted serum, while disposable indium tin oxide electrodes measured alpha-synuclein directly in cerebrospinal fluid at 0.135 picograms per milliliter. Surface plasmon resonance systems with magnetic nanoparticle amplification reached 5.6 picograms per milliliter in serum, and an organic electrolyte-gated field-effect transistor aptasensor combined with soft microfluidics detected alpha-synuclein in saliva, a completely non-invasive sample, down to 10 femtograms per liter. On the DJ-1 front, a nanocomposite-based disposable sensor achieved an extraordinary 0.5 femtograms per milliliter detection limit in cerebrospinal fluid and saliva. Microfluidic devices that isolate neuronal exosomes from less than 50 microliters of untreated serum in 30 minutes, and an integrated biochip that validated L1CAM-positive vesicle levels across 76 human serum samples, demonstrate how the field is moving from single-analyte electrodes toward complete liquid biopsy platforms.

Prion diseases, though rare, present unique diagnostic urgency because of their rapid, uniformly fatal course and their infectious biology. Conventional confirmation still relies on post-mortem immunohistochemistry, while cerebrospinal fluid real-time quaking-induced conversion assays, though highly specific, require lengthy analysis and laboratory infrastructure. Biosensor innovations are addressing this gap: surface plasmon resonance systems exploit the spontaneous binding of pathological prion protein to bare gold, photoelectrochemical immunosensors use hemin-induced photocurrent switching for ultrasensitive detection, and a magnetic microparticle multimer detection system on a recyclable boron-doped diamond electrode successfully differentiated diseased from healthy sheep plasma. Most remarkably, the Micro-QuIC platform uses acoustic microflows in PDMS microchannels to accelerate prion replication kinetics, cutting analysis time from roughly 50 hours to about three hours, a breakthrough that could also apply to Alzheimer’s, Parkinson’s, and ALS diagnostics.

Yet the review is emphatic that ultralow detection limits alone do not make a clinically useful diagnostic. Biofouling, matrix effects from abundant serum proteins, batch-to-batch variability in recognition elements, limited long-term sensor stability, complex fabrication, and above all insufficient clinical validation in large, representative patient cohorts remain formidable barriers. Most published platforms have been tested only in buffer solutions or spiked biological matrices, and few have been benchmarked against established reference methods such as amyloid PET, validated cerebrospinal fluid assays, or seed amplification tests. Multicenter studies, standardized pre-analytical protocols, reproducible large-scale manufacturing, and regulatory-grade validation are all prerequisites for translation.

The commercial landscape reflects this imbalance. Alzheimer’s disease diagnostics have advanced furthest: the FDA authorized the Lumipulse G beta-amyloid ratio cerebrospinal fluid test in 2022, cleared the first blood-based test for amyloid pathology, the Lumipulse G pTau217/beta-amyloid 1-42 plasma ratio, in May 2025, and cleared the Roche Elecsys Phospho-Tau (181P) plasma test in October 2025. Laboratory-developed tests such as PrecivityAD2 and ALZpathDx are also commercially available. By contrast, Parkinson’s disease and prion diagnostics remain confined to specialized laboratory-developed tests like the SAAmplify-alphaSYN seed amplification assay and the Syn-One skin biopsy test, with no portable point-of-care biosensor devices yet on the market.

Looking ahead, the authors argue that the convergence of biosensors with microfluidics, artificial intelligence, and wearable technology could finally deliver accessible, patient-friendly screening for neurodegenerative diseases. Integrating sensor data with clinical variables such as age, medication use, and sampling time could improve the interpretation of subtle biomarker fluctuations and enable longitudinal monitoring of disease progression. The message of the review is ultimately one of disciplined optimism: the analytical chemistry is largely in place, with sensors capable of detecting the molecular fingerprints of Alzheimer’s, Parkinson’s, and prion diseases at extraordinary sensitivity, but the path to the clinic now runs through rigorous validation, standardization, and scalable engineering rather than through ever-lower detection limits alone.

Subject of Research: Miniaturized biosensor platforms for early detection of neurodegenerative disease biomarkers and their clinical translation

Article Title: Miniaturized biosensor platforms for early detection of neurodegenerative diseases and their potential for clinical translation

Article References: Miniaturized biosensor platforms for early detection of neurodegenerative diseases and their potential for clinical translation. (n.d.). https://doi.org/10.1007/s44373-026-00171-w

Image Credits: AI Generated

DOI: 10.1007/s44373-026-00171-w

Keywords: biosensors, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, prion diseases, amyloid-beta, tau protein, alpha-synuclein, microfluidics, point-of-care diagnostics, biomarkers, clinical translation

The central biological puzzle has never changed. Prion diseases, including Creutzfeldt-Jakob disease in humans, scrapie in sheep, and chronic wasting disease in deer, are driven by the misfolding of a normal cell-surface protein, the prion protein PrP, into a self-propagating pathogenic conformer known as PrP-Sc. Unlike viruses or bacteria, this infectious entity carries no genome; its biological information is encoded purely in protein conformation. Once a misfolded seed appears, it templates the conversion of the native, protease-sensitive PrP into more of the pathological form, which then aggregates into amyloid fibrils that accumulate in the brain and destroy neurons. Caughey recognized early on that every step of this chain, from the initial conformational conversion to fibril assembly, disassembly, and clearance, represents a potential point of therapeutic attack.

Some of the earliest and most influential work from the Caughey laboratory concerned the structural chemistry of the scrapie-associated protein itself. In 1991, using infrared spectroscopy, Caughey and colleagues demonstrated that the protease-resistant PrP 27-30 core is dominated by beta-sheet secondary structure, a finding that established the conformational difference between the normal and pathological protein and set the stage for decades of structural pharmacology. This was followed by the discovery that sulfated glycosaminoglycans and dyes such as Congo red bind to PrP and block its pathological accumulation, providing the first chemical handles on the conversion process. These studies established a recurring theme: molecules that preferentially interact with amyloid-like surfaces or with the conversion intermediate can inhibit prion propagation, even if their potency in living animals remains limited by permeability and toxicity constraints.

Perhaps the most consequential technical achievement was the development of cell-free conversion assays. In the mid-1990s, Caughey and collaborators showed that aggregates of scrapie-associated PrP could induce the conversion of normal, protease-sensitive PrP to the protease-resistant state in a cell-free system. This single experiment provided powerful biochemical support for the protein-only hypothesis of prion replication and, more practically, created a screening platform. For the first time, researchers could monitor protein misfolding in real time, quantitatively, without infecting animals. The approach matured into real-time quaking-induced conversion, or RT-QuIC, an ultrasensitive amplification assay now used worldwide to detect minute quantities of prion seeding activity in cerebrospinal fluid and other tissues. RT-QuIC has become a clinical diagnostic cornerstone for sporadic and genetic Creutzfeldt-Jakob disease, and it also serves as a critical readout in therapeutic trials, allowing researchers to verify that a candidate treatment genuinely reduces the load of seed-competent misfolded protein.

Armed with these assays, the laboratory systematically screened thousands of drugs and natural products for anti-prion activity. The resulting chemical catalogue is remarkably diverse. Congo red and its analogues, sulfated polyanions, curcumin, synthetic peptides, degenerate phosphorothioate oligonucleotides, and cyclic tetrapyrroles such as porphyrins and phthalocyanines all showed the ability to inhibit protease-resistant PrP formation in cell culture or cell-free systems. Some of these compounds, notably certain porphyrins, extended survival in prion-infected mice after intracerebral challenge, while combination treatments demonstrated that pairing compounds with complementary mechanisms can enhance antiscrapie effects. Equally important was what these experiments taught about failure modes. Work on drug resistance revealed that prions can select for inhibitor-resistant conformations under selective pressure, much as viruses do, meaning that any future therapy must be designed with an eye toward the evolving conformational landscape of the infectious agent.

A second major line of investigation focused on the cell biology of the prion protein. Caughey’s group showed that the scrapie-associated form of PrP derives from a cell surface precursor that is sensitive to both proteases and phospholipases, implicating the plasma membrane as a site of conversion. The glycophosphatidylinositol anchor and the N-linked glycans of PrP were found to influence strain-dependent conformations, linking the molecule’s membrane context to its pathological folding pathway. This cellular perspective suggested therapeutic strategies that go beyond simply blocking conversion: relocating the normal protein substrate away from the compartments where conversion occurs, promoting its removal, or downregulating its expression altogether. Experiments in which neuronal depletion of PrP prevented disease and reversed early spongiform changes in infected mice validated the substrate-targeting logic, and the recent finding that depleting neuronal Ndst1 accelerates prion protein clearance and slows neurodegeneration shows that modifying the protein’s glycan environment remains a viable therapeutic direction.

More recent work from the group has pushed the substrate-targeting strategy into the era of modern nucleic acid therapeutics. Antisense oligonucleotides designed to reduce PrP expression have extended survival in prion-infected mice, and intracerebral infusion studies established proof of concept for delivering these drugs to the central nervous system. Newer reports describe divalent siRNA approaches and the inhibition of the oligosaccharyltransferase complex, which disrupts PrP maturation and effectively treats both rodent and human prions in model systems. Human cerebral organoids have emerged as a clinically relevant screening platform for Creutzfeldt-Jakob disease therapeutics, bridging the gap between cell lines and animal models. Together, these advances suggest that the long-elusive goal of an effective anti-prion treatment may finally be within reach of clinical translation, even though no approved therapy yet exists for these uniformly fatal diseases.

The review also emphasizes how high-resolution structural biology has changed the game. For decades, the infectious prion resisted atomic-level characterization because brain-derived fibrils are heterogeneous and difficult to purify. That barrier has now fallen. Cryo-electron microscopy structures of infectious mammalian prion fibrils, including anchorless RML prions and natural chronic wasting disease fibrils from deer, have revealed parallel in-register intermolecular beta-sheet architectures and defined the conformational motifs that distinguish prion strains. These structures confirm predictions made years earlier by hydrogen-deuterium exchange and other lower-resolution methods, and they open the door to genuine structure-based drug design: small molecules and designed peptides can now be engineered to bind specific pockets or surfaces on the pathogenic fibril rather than discovered by chance. Iterative machine learning approaches, already used to design potent inhibitors of alpha-synuclein and tau aggregation, are being adapted to the prion field, using fibril amplification assays with brain-derived seeds as the feedback loop.

One of the most striking lessons of this four-decade effort is its relevance far beyond the rare diseases that motivated it. Self-propagating misfolded proteins underlie Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, and other common neurodegenerative conditions, and the methodological toolkit built in the prion field, from RT-QuIC and seed amplification assays to structure-guided inhibitor design and substrate-lowering nucleic acid drugs, has been exported almost wholesale to these larger fields. Sensitive detection of misfolded protein seeds in biofluids now enables early diagnosis and objective biomarker monitoring in clinical trials, while drug design pipelines that once screened blindly can target specific fibril polymorphs. The prion concept has also reshaped thinking about biosafety, with rigorous work on disinfectants such as sodium hypochlorite and Wex-cide defining how to inactivate these exceptionally resistant agents in clinical and laboratory settings.

The Caughey story is ultimately a case study in how persistent, mechanistically grounded basic research can convert a scientific pariah into a therapeutic roadmap. By elucidating disease biochemistry, insisting on the need to target conformational change, building assays that measure the pathogenic process directly, and integrating those assays with structural characterization and cell physiology, one laboratory’s quest for prion inhibitors has given neurodegeneration research its most rigorous experimental standards. As antisense oligonucleotides, siRNA platforms, prion vaccines, and structure-based small molecule design converge, the patients and families affected by these devastating diseases have, for the first time in the history of the field, multiple credible paths toward an effective treatment, each one built on foundations laid over forty years of work at the interface of chemistry, structure, and cell physiology.

Subject of Research: Development of therapeutic inhibitors targeting prion protein misfolding through biochemistry, structural biology, and cell physiology

Article Title: Life at the interface: Byron Caughey’s search for prion disease inhibitors through chemistry, structure, and cell physiology

Article References: Life at the interface: Byron Caughey’s search for prion disease inhibitors through chemistry, structure, and cell physiology. (n.d.). https://doi.org/10.1007/s00401-026-03080-9

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03080-9

Keywords: prion diseases, prion protein, PrP-Sc, Congo red, RT-QuIC, antisense oligonucleotides, cryo-EM, drug discovery, neurodegeneration, protein misfolding, Creutzfeldt-Jakob disease, Byron Caughey